Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 326

1.

Creation of a histone deacetylase 6 inhibitor and its biological effects [corrected].

Lee JH, Yao Y, Mahendran A, Ngo L, Venta-Perez G, Choy ML, Breslow R, Marks PA.

Proc Natl Acad Sci U S A. 2015 Sep 29;112(39):12005-10. doi: 10.1073/pnas.1515882112. Epub 2015 Sep 14. Erratum in: Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):E5899.

2.

HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration.

Mielcarek M, Landles C, Weiss A, Bradaia A, Seredenina T, Inuabasi L, Osborne GF, Wadel K, Touller C, Butler R, Robertson J, Franklin SA, Smith DL, Park L, Marks PA, Wanker EE, Olson EN, Luthi-Carter R, van der Putten H, Beaumont V, Bates GP.

PLoS Biol. 2013 Nov;11(11):e1001717. doi: 10.1371/journal.pbio.1001717. Epub 2013 Nov 26.

3.

Development of a histone deacetylase 6 inhibitor and its biological effects.

Lee JH, Mahendran A, Yao Y, Ngo L, Venta-Perez G, Choy ML, Kim N, Ham WS, Breslow R, Marks PA.

Proc Natl Acad Sci U S A. 2013 Sep 24;110(39):15704-9. doi: 10.1073/pnas.1313893110. Epub 2013 Sep 10.

4.

Mechanisms of resistance to histone deacetylase inhibitors.

Lee JH, Choy ML, Marks PA.

Adv Cancer Res. 2012;116:39-86. doi: 10.1016/B978-0-12-394387-3.00002-1. Review.

PMID:
23088868
5.

Curbing autophagy and histone deacetylases to kill cancer cells.

Gammoh N, Marks PA, Jiang X.

Autophagy. 2012 Oct;8(10):1521-2. doi: 10.4161/auto.21151. Epub 2012 Aug 16.

6.

Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death.

Gammoh N, Lam D, Puente C, Ganley I, Marks PA, Jiang X.

Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6561-5. doi: 10.1073/pnas.1204429109. Epub 2012 Apr 9.

7.

SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease.

Mielcarek M, Benn CL, Franklin SA, Smith DL, Woodman B, Marks PA, Bates GP.

PLoS One. 2011;6(11):e27746. doi: 10.1371/journal.pone.0027746. Epub 2011 Nov 28.

8.

Histone deacetylase inhibitors in the therapy of cancer: much to learn.

Lee JH, Marks PA.

Epigenomics. 2010 Dec;2(6):723-5. doi: 10.2217/epi.10.59. No abstract available.

9.

Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors.

Lee JH, Choy ML, Ngo L, Venta-Perez G, Marks PA.

Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19629-34. doi: 10.1073/pnas.1117544108. Epub 2011 Nov 21.

10.

Epigenetic targeted anti-cancer drugs: an unfolding story.

Marks PA.

Oncology (Williston Park). 2011 Mar;25(3):231, 235. No abstract available.

11.

Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents.

Namdar M, Perez G, Ngo L, Marks PA.

Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20003-8. doi: 10.1073/pnas.1013754107. Epub 2010 Oct 29.

12.

The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.

Marks PA.

Expert Opin Investig Drugs. 2010 Sep;19(9):1049-66. doi: 10.1517/13543784.2010.510514. Review.

13.

Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.

Lee JH, Choy ML, Ngo L, Foster SS, Marks PA.

Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14639-44. doi: 10.1073/pnas.1008522107. Epub 2010 Aug 2.

14.

Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.

Marks PA.

Biochim Biophys Acta. 2010 Oct-Dec;1799(10-12):717-25. doi: 10.1016/j.bbagrm.2010.05.008. Epub 2010 Jun 8. Review.

15.

Body composition and energy metabolism following Roux-en-Y gastric bypass surgery.

Tamboli RA, Hossain HA, Marks PA, Eckhauser AW, Rathmacher JA, Phillips SE, Buchowski MS, Chen KY, Abumrad NN.

Obesity (Silver Spring). 2010 Sep;18(9):1718-24. doi: 10.1038/oby.2010.89. Epub 2010 Apr 22.

16.

HDAC inhibitors: much to learn about effective therapy.

Marks PA.

Oncology (Williston Park). 2010 Feb;24(2):185, 188. No abstract available.

17.

Histone deacetylase inhibitors: Potential in cancer therapy.

Marks PA, Xu WS.

J Cell Biochem. 2009 Jul 1;107(4):600-8. doi: 10.1002/jcb.22185. Review.

18.

Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.

Poulaki V, Mitsiades CS, Kotoula V, Negri J, McMullan C, Miller JW, Marks PA, Mitsiades N.

Invest Ophthalmol Vis Sci. 2009 Sep;50(9):4072-9. doi: 10.1167/iovs.09-3517. Epub 2009 Apr 22.

PMID:
19387079
19.

HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation.

Parmigiani RB, Xu WS, Venta-Perez G, Erdjument-Bromage H, Yaneva M, Tempst P, Marks PA.

Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9633-8. doi: 10.1073/pnas.0803749105. Epub 2008 Jul 7.

20.

The American Society for Clinical Investigation--the first 100 years.

Marks PA.

J Clin Invest. 2008 Apr;118(4):1223-4. doi: 10.1172/JCI34805.

21.

Histone deacetylase inhibitors: overview and perspectives.

Dokmanovic M, Clarke C, Marks PA.

Mol Cancer Res. 2007 Oct;5(10):981-9. Review.

22.

Histone deacetylase inhibitors selectively suppress expression of HDAC7.

Dokmanovic M, Perez G, Xu W, Ngo L, Clarke C, Parmigiani RB, Marks PA.

Mol Cancer Ther. 2007 Sep;6(9):2525-34.

23.

Histone deacetylase inhibitors: molecular mechanisms of action.

Xu WS, Parmigiani RB, Marks PA.

Oncogene. 2007 Aug 13;26(37):5541-52. Review.

PMID:
17694093
24.

Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma.

Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L, Williams S, Wiegmans AP, Dear AE, Scott CL, Pellegrini M, Wei A, Richon VM, Marks PA, Lowe SW, Smyth MJ, Johnstone RW.

Proc Natl Acad Sci U S A. 2007 May 8;104(19):8071-6. Epub 2007 Apr 30.

25.

Discovery and development of SAHA as an anticancer agent.

Marks PA.

Oncogene. 2007 Feb 26;26(9):1351-6. Review.

PMID:
17322921
26.

Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.

Marrocco DL, Tilley WD, Bianco-Miotto T, Evdokiou A, Scher HI, Rifkind RA, Marks PA, Richon VM, Butler LM.

Mol Cancer Ther. 2007 Jan;6(1):51-60. Epub 2007 Jan 11.

27.
28.

Thioredoxin in cancer--role of histone deacetylase inhibitors.

Marks PA.

Semin Cancer Biol. 2006 Dec;16(6):436-43. Epub 2006 Sep 26. Review.

29.

A man who has made his Marks on science.

Honey K, Marks PA.

J Clin Invest. 2006 Nov;116(11):2833. No abstract available.

30.

Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor.

Xu W, Ngo L, Perez G, Dokmanovic M, Marks PA.

Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15540-5. Epub 2006 Oct 9.

31.

Histone deacetylase inhibitors: discovery and development as anticancer agents.

Marks PA, Dokmanovic M.

Expert Opin Investig Drugs. 2005 Dec;14(12):1497-511. Review.

PMID:
16307490
32.
33.

Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects.

Xu WS, Perez G, Ngo L, Gui CY, Marks PA.

Cancer Res. 2005 Sep 1;65(17):7832-9.

34.

Prospects: histone deacetylase inhibitors.

Dokmanovic M, Marks PA.

J Cell Biochem. 2005 Oct 1;96(2):293-304. Review.

PMID:
16088937
35.

Novel histone deacetylase inhibitors in the treatment of thyroid cancer.

Mitsiades CS, Poulaki V, McMullan C, Negri J, Fanourakis G, Goudopoulou A, Richon VM, Marks PA, Mitsiades N.

Clin Cancer Res. 2005 May 15;11(10):3958-65.

36.

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.

Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM.

J Clin Oncol. 2005 Jun 10;23(17):3923-31. Epub 2005 May 16.

37.

Histone deacetylase inhibitors in programmed cell death and cancer therapy.

Marks PA, Jiang X.

Cell Cycle. 2005 Apr;4(4):549-51. Epub 2005 Apr 28. Review.

PMID:
15738652
38.

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.

Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA, Holloway AJ, Johnstone RW.

Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3697-702. Epub 2005 Feb 28.

39.

Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors.

Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X, Marks PA.

Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):673-8. Epub 2005 Jan 6.

40.

Apoptotic and autophagic cell death induced by histone deacetylase inhibitors.

Shao Y, Gao Z, Marks PA, Jiang X.

Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18030-5. Epub 2004 Dec 13.

41.

Blasts from the past.

Insel PA, Kornfeld S, Majerus PW, Marks AR, Marks PA, Relman AS, Scharschmidt BF, Stossel TP, Varki AP, Weiss SJ, Wilson JD.

J Clin Invest. 2004 Oct;114(8):1017-33.

42.

Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid.

Reilly CM, Mishra N, Miller JM, Joshi D, Ruiz P, Richon VM, Marks PA, Gilkeson GS.

J Immunol. 2004 Sep 15;173(6):4171-8.

43.

Histone deacetylase inhibitors.

Marks PA, Richon VM, Miller T, Kelly WK.

Adv Cancer Res. 2004;91:137-68. Review.

PMID:
15327890
44.

Histone deacetylase inhibitors: development as cancer therapy.

Marks PA, Richon VM, Kelly WK, Chiao JH, Miller T.

Novartis Found Symp. 2004;259:269-81; discussion 281-8.

PMID:
15171260
45.
46.

Histone deacetylase inhibitors: assays to assess effectiveness in vitro and in vivo.

Richon VM, Zhou X, Secrist JP, Cordon-Cardo C, Kelly WK, Drobnjak M, Marks PA.

Methods Enzymol. 2004;376:199-205. Review. No abstract available.

PMID:
14975307
47.

Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1.

Gui CY, Ngo L, Xu WS, Richon VM, Marks PA.

Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1241-6. Epub 2004 Jan 20.

48.

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.

Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks PA, Anderson KC.

Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):540-5. Epub 2003 Dec 26.

49.

Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro.

Kutko MC, Glick RD, Butler LM, Coffey DC, Rifkind RA, Marks PA, Richon VM, LaQuaglia MP.

Clin Cancer Res. 2003 Nov 15;9(15):5749-55.

50.

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3578-88.

Supplemental Content

Loading ...
Support Center